Oral and Skin Pigmentations associated with hydroxyurea therapeutic doses in a patient with sickle cell disease: Case Report
Article Sidebar
Main Article Content
Abstract
Hydroxyurea is an effective treatment for Sickle cell disease. Hydroxyurea has classified as an antineoplastic agent and is also prescribed as Antisickling agent; it works through inhibition of DNA synthesis at S phase. Despite Hydroxyurea benefits sickle cell patients, undesirable side effect such as leukopenia and hyperpigmentation were observed. Hydroxyurea-induced hyperpigmentation is mainly seen in the skin and rarely in the oral cavity. Although Hydroxyrea-induced pigmentation is benign and reversible, this mild pathological condition should have considered.
Downloads
Article Details
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the Sebha University, where authors who have published their articles in the Sebha University journal can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
- Privacy Statement The names and e-mail addresses entered on the Sebha University Journal site will be used for the aforementioned purposes only and for which they were used.
